Cardiology
Conditions
Interventions
Sponsors
Dr. Abeng Mbina Adomi
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Pregnant women diagnosed with severe preeclampsia based on the clinical criteria (systolic blood pressure =160 mmHg and diastolic blood pressure =110 mmHg on two occasions at least 4 hours apart, with proteinuria or evidence of end-organ dysfunction). 2. Gestational age =28 weeks. 3. Singleton pregnancy. 4. Ability to provide informed consent to participate in the study. 5. Pregnant women aged <19 to 44 years.
Exclusion criteria
Exclusion criteria: 1. Contraindications to labetalol or hydralazine, such as asthma, or known hypersensitivity. 2. History of chronic hypertension or pre-existing cardiovascular disease. 3. Known renal or hepatic dysfunction prior to pregnancy. 4. Women with eclampsia or requiring emergency delivery at the time of presentation. 5. Any condition or comorbidity that, in the opinion of the investigator, would interfere with participation in the study or compromise participant safety 6. Pregnant women age 44 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.The time required for intravenous labetalol and intravenous hydralazine to lower blood pressure to below 150/100 mmHg in patients with severe preeclampsia. 2.The number of doses of both drugs needed to get the desired blood pressure | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The side effects of the medication on mothers, fetuses, and neonates born during the study period | — |
Countries
Nigeria
Contacts
Public ContactAkpan Ubong
Supervisor
Outcome results
None listed